文献速递创面修复烧伤瘢痕与激光

儿童培养自体真皮-表皮皮肤替代物长期结局:I期临床试验5年结果

Long-Term Outcomes of a Cultured Autologous Dermo-Epidermal Skin Substitute in Children: 5-Year Results of a Phase I Clinical Trial.
PubMed 文献 · J Burn Care Res · 2025-01-01

该I期临床试验旨在评估实验室培养的自体双层皮肤替代物(denovoSkin)治疗儿童大面积皮肤缺损的长期安全性。10例患儿移植后每年随访至5年,7例完成5年随访;皮肤替代物持续安全、稳定、无脆弱或肿瘤形成,瘢痕质量接近正常皮肤。一项多中心前瞻性随机II期临床试验正在进行中。

要点

  • 10例患儿中7例完成5年随访,皮肤替代物持续安全稳定。
  • 临床检查无脆弱迹象、无肿瘤形成,瘢痕质量接近正常皮肤。
  • 多中心前瞻性随机II期临床试验正在进行以进一步评估安全性和有效性。

核心结论

  • 儿童实验室培养皮肤替代物移植至今被认为安全,功能与美学长期结果接近正常皮肤,结果令人鼓舞,凸显其作为大面积皮肤缺损救命疗法的潜力。

研究设计与样本

  • I期临床试验,10例儿童患者移植denovoSkin后每年随访至5年,报告48个月长期结果,7例完成5年随访期。

主要发现

  • 皮肤替代物持续被认为安全、保持稳定且几乎无变化,临床检查无脆弱迹象、无肿瘤形成。
  • 使用患者与观察者瘢痕评估量表评估的瘢痕质量接近正常皮肤。

局限性

  • 10例患者中仅7例完成5年随访期。
  • 原文指出一项多中心前瞻性随机II期临床试验正在进行以进一步评估安全性和有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Limited donor sites and poor long-term outcomes with standard treatment for large skin defects remain a huge problem. An autologous, bilayered, laboratory-grown skin substitute (denovoSkin) was developed to overcome this problem and has shown to be safe in 10 pediatric patients in a Phase I clinical trial after transplantation. The goal of this article was to report on 48-month long-term results. The pediatric participants of the phase I clinical trial were followed up at yearly visits up to 5 years after transplantation. Safety parameters, including the occurrence of adverse events, possible deviations of vital signs, and changes in concomitant therapy as well as additional parameters regarding skin stability, scar quality, and tumor formation, were assessed. Furthermore, scar maturation was photographically documented. Of the 10 patients treated with denovoSkin in this phase I clinical trial, 7 completed the 5-year follow-up period. Skin substitutes continued to be deemed safe, remained stable, and practically unchanged, with no sign of fragility and no tumor formation at clinical examination. Scar quality, captured using the Patient and Observer Scar Assessment Scale, was evaluated as close to normal skin. Transplantation of this laboratory-grown skin substitute in children is to date considered safe and shows encouraging functional and aesthetical long-term results close to normal skin. These results are promising and highlight the potential of a life-saving therapy for large skin defects. A multicentre, prospective, randomized, phase II clinical trial is currently ongoing to further evaluate the safety and efficacy of this novel skin substitute. Clinicaltrials.gov identifier NCT02145130.

来源:J Burn Care Res,查看原文。版权归原作者所有。

引用

  1. Schiestl C, Neuhaus K, Meuli M, et al. Long-Term Outcomes of a Cultured Autologous Dermo-Epidermal Skin Substitute in Children: 5-Year Results of a Phase I Clinical Trial. J Burn Care Res. 2025. PMID: 39115183. doi:10.1093/jbcr/irae150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。